A phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer
The Oncologist Mar 05, 2018
Wei XX, et al. - This phase II trial demonstrated clinical activity and poor tolerability of selinexor in metastatic castration-resistant prostate cancer patients refractory to second-line anti-androgenic agents.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries